Amicus Therapeutics, Inc. (FOLD) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals mixed signals. Financial performance shows increased expenses and net loss, though non-GAAP income remains positive. Product development and market expansion are promising, with strong market share gains and regulatory progress. However, the decreased revenue growth guidance and increased COGS raise concerns. The Q&A highlights confidence in IP and manufacturing progress but lacks specifics on timelines and COGS impact. Overall, the sentiment is neutral, with potential for both positive and negative market reactions.
Key Financial Performance
Galafold Revenue $128.9 million this quarter, up 12% at constant exchange rates and up 16% in reported terms. The growth is driven by the number of new patient starts globally and achieving more than 69% of the global market share for treated Fabry patients with amenable mutations.
Pombiliti and Opfolda Revenue $25.8 million this quarter, up 58% at constant exchange rates. The growth is attributed to strong sales growth, record levels of patient demand, and expansion into new markets including 5 new countries in Q2.
Total Revenue $154.7 million, a 22% increase over the same period in 2024 (18% at constant exchange rates). The growth is driven by strong performance in both Galafold and Pombiliti and Opfolda.
Cost of Goods Sold (COGS) 10% of net sales for Q2, compared to 9% in the same period last year. The slight increase is due to changes in product mix.
GAAP Operating Expenses $148.9 million for Q2 2025, up 48% from $100.4 million in Q2 2024. The increase includes a $30 million upfront payment for the U.S. licensing rights to DMX-200.
Non-GAAP Operating Expenses $127.8 million for Q2 2025, up 56% from $82.1 million in Q2 2024. The increase reflects higher R&D and SG&A expenses.
GAAP Net Loss $24.4 million or $0.08 per share for Q2 2025, compared to $15.7 million or $0.05 per share in Q2 2024. The loss includes the $30 million upfront payment for DMX-200.
Non-GAAP Net Income $1.9 million or $0.01 per share for Q2 2025, compared to $18.5 million or $0.06 per share in Q2 2024. The decrease is due to increased operating expenses.
Cash, Cash Equivalents, and Marketable Securities $231 million as of June 30, 2025, compared to $250 million as of December 31, 2024. The decrease is attributed to operational expenses and the upfront payment for DMX-200.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Galafold: Revenue reached $128.9 million this quarter, up 12% at constant exchange rates and 16% in reported terms. Achieved 69% global market share for treated Fabry patients with amenable mutations. Record high growth in naive new patient starts.
Pombiliti and Opfolda: Second quarter revenue reached $25.8 million, up 58% at constant exchange rates. Launched in 5 new markets in Q2, with strong sales growth and record levels of patient demand. Expected to contribute significantly to multiyear growth.
DMX-200: A first-in-class compound in late-stage Phase III development for a rare kidney disease. The pivotal ACTION3 study is on track for full enrollment by year-end. Positioned as a meaningful advancement for FSGS patients.
Geographic Expansion: Pombiliti and Opfolda launched in 5 new markets in Q2, including Italy, Switzerland, Portugal, Czech Republic, and Sweden. Regulatory approval received in Japan for patients aged 15 and older.
Fabry Disease Market: Over 12,000 people receive treatment worldwide, with 6,000 diagnosed patients remaining untreated. Literature suggests a larger underdiagnosed population, indicating substantial market opportunity for Galafold.
Revenue Growth: Achieved total revenue of $154.7 million in Q2 2025, a 22% increase over the same period in 2024. Galafold and Pombiliti/Opfolda are key drivers of growth.
Financial Discipline: On track to achieve GAAP profitability in the second half of 2025. Maintained strong cash position with $231 million as of June 30, 2025.
Strategic Partnership: Advanced partnership with Dimerix for DMX-200, a potential blockbuster treatment for FSGS. $30 million upfront payment made for U.S. licensing rights.
Long-term Growth: Reiterated confidence in achieving $1 billion combined sales for Pombiliti and Opfolda by 2028. Galafold projected to surpass $1 billion in revenue with strong IP protection and market expansion.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approvals and Market Access: Challenges in securing broad patient access throughout the EU for Pombiliti and Opfolda, despite recent regulatory approval in Japan.
Geographic Expansion: The need to launch Pombiliti and Opfolda in up to 10 new countries this year, which may pose logistical and operational challenges.
Financial Discipline: Increased operating expenses, including a $30 million upfront payment for DMX-200, impacting net income and cash reserves.
Product Differentiation: Efforts to differentiate Pombiliti and Opfolda through evidence generation and real-world data, which may take time to influence wider adoption.
Pipeline Development: Dependence on the successful enrollment and outcomes of the Phase III ACTION trial for DMX-200, which is critical for addressing unmet needs in FSGS.
Market Penetration: Challenges in achieving high market shares globally for Galafold, despite strong performance in mature markets.
Economic and Currency Risks: Revenue growth is reported at constant exchange rates, indicating potential exposure to currency fluctuations.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects total revenue growth of 15% to 22% for 2025, with Galafold revenue growth projected at 10% to 15% and Pombiliti and Opfolda revenue growth anticipated at 50% to 65%, all at constant exchange rates.
Product Sales Projections: Galafold is expected to surpass $1 billion in revenue, driven by new patient starts, market penetration, and high compliance rates. Pombiliti and Opfolda are projected to reach combined sales of $1 billion by the end of 2028, with peak sales potential exceeding $1 billion for each product.
Market Expansion: Pombiliti and Opfolda are set to launch in up to 10 new countries in 2025, with significant growth expected in markets like the Netherlands and Japan. Galafold is also expanding into new markets and extending its label.
Pipeline Development: The ACTION3 pivotal study for DMX-200, a treatment for FSGS, is on track for full enrollment by the end of 2025. The company plans to request an additional FDA meeting to discuss interim efficacy assessments and next steps for DMX-200.
Profitability: The company reiterates its expectation to achieve GAAP profitability in the second half of 2025.
Long-Term Growth Drivers: Key drivers include increasing patient access, expanding into new markets, enhancing diagnostic rates, and sustaining high compliance and adherence rates for its products.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What clinical assessments resonate with physicians and KOLs when switching patients from Nexviazyme to PomOp? Are there differences between the U.S. and OUS?
A:Physicians look for stability of declining function or improvements in biomarkers, muscle strength, 6-minute walk FVC, and quality of life. The process of switching from Nexviazyme to PomOp is similar to switching from Lumizyme. There is no significant difference between the U.S. and other geographies.
Q:What is the update on the additional manufacturing facility for PomOp in Ireland?
A:The Ireland facility is expected to supply global demand with material entering the commercial supply chain in Europe in the back half of this year and in the U.S. next year. A secondary site in China may serve Europe and ex-U.S. markets. The company has also started drug product manufacturing in the U.S. with Sharp.
Q:Do you still feel confident in your IP position and the potential for a settlement with Aurobindo?
A:The company remains highly confident in the strength of its IP and the long-term opportunity to support Fabry patients. The settlement with Teva reinforces confidence in the case against Aurobindo. Most cases statistically lead to settlement.
Q:How are timelines progressing for the new U.S. manufacturing process, and what is its impact on COGS?
A:The company is working through PPQs for the U.S. drug product manufacturing facility. Specific timelines have not been shared. Progress is being made on the DS side in Ireland and DP in Germany. The impact on COGS was not directly addressed.
Q:What should we expect for PomOp's launch in the next 12 months as more Nexviazyme patients approach the 2-year mark for treatment reevaluation?
A:A significant portion of Nexviazyme patients in the U.S. are reaching the 2-year mark, and many are switching to PomOp. The company expects continued growth as more patients reach this point and as physicians identify early predictors of decline.
Q:How is the current reimbursement situation for PomOp?
A:Reimbursement is progressing well in all geographies, with the company achieving first or fastest approvals in multiple markets like the U.K., Germany, and the Netherlands.
Q:Can you provide more color on how starts are going in ex-U.S. markets?
A:The U.K. has reached a 35% market share, Germany remains strong, and Spain is seeing significant inroads. Sweden has a disproportionate market share for PomOp. Six new countries have launched this year, with four more expected, including Japan.
Q:What is making patients switch from Nexviazyme to PomOp at the 2-year mark versus earlier or later?
A:Earlier switches are often due to clear declines in health, while the 2-year mark is a natural reevaluation point. Over time, the company aims to establish PomOp as the best therapy, encouraging proactive switches.
Q:Can you provide more detail on the regulatory alignment with the FDA for DMX-200 in FSGS?
A:The FDA has indicated that proteinuria could serve as the primary endpoint for the Phase III study, with GFR as a secondary endpoint. The company views the upcoming Travere AdCom as an opportunity to reinforce proteinuria as a suitable endpoint.
Q:What is the timeline for DMX-200 Phase III data, and what is the bar for success?
A:Enrollment is expected to complete by the end of this year, with last patient out by the end of 2027. The study is powered to show small changes in proteinuria, with responder thresholds below 10% being clinically meaningful.
Q:Review of Unclear Management Responses
A:Management avoided providing specific timelines for the U.S. manufacturing process and did not directly address the impact on COGS. Additionally, they could not comment further on the details of the litigation with Aurobindo due to ongoing legal proceedings.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ACTION study
Campbell
DMX class
FDA
FSGS
LLC Research
Netherlands
Phase III
Pombiliti COGS
Pombiliti Pompe
Pombiliti contributor
Pombiliti exchange
Research Division
Sebastien Slide
analysis
angiotensin receptor
case study
compliance rate
differentiation Pombiliti
effect
enrollment end
evidence differentiation
inhibitor
kidney disease
licensing
margin mids
meeting
patient Pombiliti
patient driver
payment
product sale
proteinuria
rate term
record level
track enrollment
FOLD Transcript
Amicus Therapeutics, Inc. (FOLD) Presents at UBS Global Healthcare Conference 2025 Transcript
Neutral11-10
Amicus Therapeutics, Inc. (FOLD) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call highlights strong financial performance, with significant revenue growth and a shift to GAAP profitability. Despite increased COGS, net income improved, and cash reserves grew. The Q&A section revealed positive reception of product labels and strategic market expansion plans. However, vague responses on revenue acceleration and supply stability pose some concerns. Overall, the positive financial results, optimistic guidance, and strategic initiatives outweigh these concerns, suggesting a positive stock price movement.
Amicus Therapeutics, Inc. (FOLD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Neutral9-9
Amicus Therapeutics, Inc. (FOLD) Q2 2025 Earnings Call Transcript
Unknown7-31
The earnings call reveals mixed signals. Financial performance shows increased expenses and net loss, though non-GAAP income remains positive. Product development and market expansion are promising, with strong market share gains and regulatory progress. However, the decreased revenue growth guidance and increased COGS raise concerns. The Q&A highlights confidence in IP and manufacturing progress but lacks specifics on timelines and COGS impact. Overall, the sentiment is neutral, with potential for both positive and negative market reactions.
FOLD Slides
FOLD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
